• In June 2026, a Delaware jury found that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed’s Grosveld patent, awarding Harbour US$20,203,704 in damages and opening the door to a potential trebling of the award to about US$60.61 million.
• The verdict places fresh attention on Amgen’s exposure to intellectual property disputes around its antibody discovery technology, raising questions about legal risk management and potential future royalty or licensing obligations.
• We’ll now explore how this willful infringement verdict and potential treble damages could influence Amgen’s broader investment narrative.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Amgen Investment Narrative Recap

To own Amgen, you generally need to believe its diversified therapies and late stage pipeline can offset patent pressure and pricing headwinds while supporting steady cash generation. The Harbour BioMed verdict, even if trebled to about US$60.6 million, is small relative to Amgen’s scale and current guidance, though it does sharpen attention on intellectual property risk around its antibody discovery platforms.

Against this backdrop, Amgen’s Q1 2026 results and reaffirmed full year revenue guidance of US$37.1 billion to US$38.5 billion feel particularly relevant. They show that, at least so far, the jury verdict has not led the company to change its near term financial outlook, keeping the focus on execution of key launches and biosimilar growth while investors watch how IP disputes and potential additional claims evolve.

Yet beneath the headline verdict, there is a further intellectual property overhang that investors should be aware of, including possible exposure to...

Amgen's narrative projects $40.1 billion revenue and $9.9 billion earnings by 2029. This requires 2.5% yearly revenue growth and a $2.1 billion earnings increase from $7.8 billion today.

Uncover how Amgen's forecasts yield a $352.23 fair value, in line with its current price.

Exploring Other Perspectives

While consensus still assumes mid US$37 billion revenue and earnings near US$7.9 billion by 2029, the most bearish analysts see IP and pricing pressures as reasons those expectations could prove too optimistic, so it is worth comparing their more cautious view with your own.

Explore 4 other fair value estimates on Amgen - why the stock might be worth just $352.23!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amgen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amgen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amgen's overall financial health at a glance.

No Opportunity In Amgen?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 38 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.